For your patients with HR+, HER2−, early-stage, invasive breast cancer
The Oncotype DX Breast Recurrence Score® report provides three points of clarity to aid in treatment decisions as to whether adjuvant chemotherapy is needed or not for node-negative and node-positive (N1: up to 3 positive lymph nodes), hormone receptor-positive, HER2-negative, early-stage breast cancer patients.
Use our online physician portal
Order tests securely, access results quickly, sign documents, assign delegates, receive updates and more benefits available in one place
3 pieces of information provided by the test
Recurrence Score® result
This number, between 0 and 100, is calculated by measuring the activity of specific genes in the breast cancer tissue. The Recurrence Score result is used to predict the risk of the breast cancer returning at a distant site and whether chemotherapy may help reduce the risk.1-5
Distant recurrence riska
This percentage indicates the risk that the breast cancer will come back somewhere else in the body, “distant recurrence,” within 10 years (node-negative)1,6 or 5 years (node-positive)4,9,10 when treated with hormonal therapy alone for 5 years.
Absolute chemotherapy benefita
This percentage indicates the benefit expected for the Recurrence Score group from adding chemotherapy to hormonal therapy in order to reduce the risk of cancer recurrence or death.2-4, 8-10
- These results are valid in HR+, HER2-, early-stage, invasive breast cancer patients treated with 5 years of endocrine therapy.
Explore the patient reports
Node-Negative
Loading component...
Node-Positive
Loading component...
Further understanding the results
Node-negative patients
Patients with a Recurrence Score result of 0-25 generally do not benefit from the addition of chemotherapy to endocrine therapy.2,3,6,7
For patients under 50 years of age or younger there is some chemotherapy benefit (in terms of DRFI) for those with Recurrence Score result:6,7
Patients with Recurrence Score results 26–100 have a significant and increasing benefit from the addition of chemotherapy to endocrine therapy.2,3
For patients under 50 years of age or younger there is some chemotherapy benefit (in terms of DRFI) for those with Recurrence Score result:
- 16-20 and high clinical risk
- 21-25 regardless of clinical risk
Patients with Recurrence Score results 26–100 have a significant and increasing benefit from the addition of chemotherapy to endocrine therapy.
Node-positive patients
Post-menopausal patients with a Recurrence Score result of 0–25 do not benefit from the addition of chemotherapy to endocrine therapy.4,8,9
Pre-menopausal patients with Recurrence Score results of 0-25 have a 2.4% benefit (in terms of DRFI) from the addition of chemotherapy to endocrine therapy.8,9
All patients with Recurrence Score results 26-100 significantly benefit from the addition of chemotherapy to endocrine therapy.4
Pre-menopausal patients with Recurrence Score results of 0-25 have a 2.4% benefit (in terms of DRFI) from the addition of chemotherapy to endocrine therapy.
All patients with Recurrence Score results 26-100 significantly benefit from the addition of chemotherapy to endocrine therapy.
Abbreviations
References
Get in touch
Have questions about Oncotype DX?
